Abstracts tagged "glucocorticoids"

Abstract Number: 2372 • ACR Convergence 2024
Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Yoo Jin Kim¹, Jana Lovell¹, Alaa Diab¹, Laurence Magder², Daniel Goldman³, Michelle Petri³, Luigi Adamo¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Baltimore, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE). In the general population, pericarditis commonly recurs (~30%), likely due to immune-mediated…
Abstract Number: 2606 • ACR Convergence 2024
Changes in Long-term GC Use Among Older Adults After New Diagnosis of Late-onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Beth Wallace², Namrata Singh³, Una Makris⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Washington, Bellevue, WA, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Older adults with late-onset rheumatoid arthritis (LORA) receive less disease-modifying anti-rheumatic drugs (DMARDs), which is the standard of care. In contrast, long-term glucocorticoid (GC)…
Abstract Number: 0774 • ACR Convergence 2024
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Peter Merkel¹, Christian Pagnoux², Nader Khalidi³, Ulrich Specks⁴, Curry Koening⁵, Carol Langford⁶, Larry Moreland⁷, Paul Monach⁸, Jason Springer⁹, Shubhasree Banerjee¹, Simon Carette¹⁰, Rennie Rhee¹, Medha Soowamber¹¹, Kenneth Warrington⁴, Renee Borchin¹², Cristina Burroughs¹³, Carol McAlear¹, David Cuthbertson¹³ and Jeffrey Krischer¹³, ¹University of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hospital, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Mayo Clinic, Rochester, MN, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Colorado, Denver, CO, ⁸VA Boston Healthcare System, Boston, MA, ⁹Vanderbilt University Medical Center, Franklin, TN, ¹⁰Mount Sinai Hosptial, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of South Florida, Tampa, ¹³University of South Florida, Tampa, FL
Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial. Additionally, there is no consensus on how to…
Abstract Number: 1695 • ACR Convergence 2024
Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Peter Merkel¹, Arathi Setty², Ricardo Blanco-Alonso³, Ravi Suppiah⁴, Thomas Daikeler⁵, Valerie Devauchelle⁶, Elisabeth Brouwer⁷, Hiromichi Tamaki⁸, Liu Meng², Yang Yang², Avani Joshi², Charles Phillips², Peter K. Wung² and Cristina Ponte⁹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, ⁵university hospital, Basel, Switzerland, ⁶UBO, Brest, France, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
Abstract Number: 2419 • ACR Convergence 2024
Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
Richard Furie¹, Mawuena Binka², Gelareh Atefi³, Stephanie Y. Chen⁴ and Bo Ding⁵, ¹Northwell Health, Manhasset, NY, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ³AstraZeneca, Media, PA, ⁴BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE is an autoimmune disease with diverse manifestations and progression patterns that, via disease activity and effects of standard therapy, imposes a significant burden…
Abstract Number: 2648 • ACR Convergence 2024
Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging
Vicente Aldasoro¹, Vicky Betech-Antar², Santos Castañeda³, Eugenio De Miguel⁴, Juan José Rosales⁵ and Maria Jose García Velloso⁵, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Clinica Universidad de Navarra, Pamplona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Clínica Universidad de Navarra, Pamplona, Spain
Background/Purpose: The aim of this study is to analyse the diagnostic value of the delay images at 180 minutes in positron emission tomography (PET) performed in…
Abstract Number: 0858 • ACR Convergence 2024
Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)
Alain SARAUX¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, christian roux⁴, Christophe Richez⁵, Alice TISON⁶, Baptiste Quere⁷, Sandrine Jousse-Joulin⁸, Dewi Guellec⁷, Thierry Marhadou⁹, Patrice Kervarrec⁷, Divi Cornec¹⁰, Catherine Le Henaff⁷, Sandra Lesven⁷, nowak emmanuel⁷, Aghiles Souki⁷ and Valerie Devauchelle¹¹, ¹CHU Brest, Brest, France, ²CHRU de Tours, Tours, France, ³CH LE MANS, LE MANS, Pays de la Loire, France, ⁴rheumatology department, university Cote d'Azur, nice, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶CHU de la Cavale Blanche, Brest, France, Brest, France, ⁷Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ⁸cavale blanche hospital, brest, France, ⁹CHU Cavale Blanche, Brest, France, ¹⁰University of Brest, Brest, France, ¹¹UBO, Brest, France
Background/Purpose: Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients. The purpose of this…
Abstract Number: 1700 • ACR Convergence 2024
Comparative Effectiveness of Sarilumab vs. Methotrexate as a Glucocorticoid-Sparing Agent in Patients with Polymyalgia Rheumatica
Jeffrey Curtis¹, Fenglong Xie², Shanette Daigle³ and Sebastian E. Sattui⁴, ¹The University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³FASTER, Birmingham, AL, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that typically affects older individuals for whom long term glucocorticoid (GC) use may be undesirable. Moreover, the…
Abstract Number: 2421 • ACR Convergence 2024
Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
Mariana Gonzalez-Trevino¹, Jaime Flores Gouyonnet¹, Qiping Xu², Cassondra Hulshizer³, Jose Meade-Aguilar⁴, Erika Navarro-Mendoza¹, Mario Bautista-Vargas⁵, Gabriel Figueroa-Parra⁶, Alain Sanchez-Rodriguez⁷, Maria Cuellar-Gutierrez¹, Andrew C. Hanson⁸, Cynthia Crowson¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Health System - Mankato, Mankato, MN, ³Mayo Clinic, Utica, MN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁷Mayo Clinic College of Medicine and Science, Rochester, MN, ⁸Mayo Clinic, Rochester
Background/Purpose: We examined the patterns of glucocorticoid (GC) use and the temporal trends of GC initiation, discontinuation, and reduction over four decades in a population-based…
Abstract Number: 2673 • ACR Convergence 2024
Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis
Diane Lacaille¹, Coraline Danieli², Kasra Moolooghy¹ and Michal Abrahamowicz³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, ³McGill University, Verdun, Canada
Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
Abstract Number: 0975 • ACR Convergence 2024
Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Sebastian E. Sattui¹, FRANK HARTMUT DR. BUTTGEREIT², Merav Lidar³, Kerri Ford⁴, Stefano Fiore⁵, Lita Araujo⁴, Timothy Beukelman⁶, Fenglong Xie⁷ and Jeffrey Curtis⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Charité University Medicine Berlin, Berlin, Germany, ³Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Bridgewater, NJ, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the…
Abstract Number: 1719 • ACR Convergence 2024
Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study
Beth Wallace¹, Yuqing Gao², H. Myra Kim³, Bryant England⁴, Sauer brian⁵, grant Cannon⁶, Punyasha Roul⁷, Ted Mikuls⁴, Shirley Cohen-Mekelburg⁸, Daniel Clauw⁹, Wyndy Wiitala², Rodney Hayward¹⁰, Jeremy Sussman¹¹ and Akbar Waljee¹¹, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Michigan School of Public Health, Ann Arbor, MI, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Michigan Department of Internal Medicine, Division of Gastroenterology, Ann Arbor, MI, ⁹University of Michigan, Whitmore Lake, MI, ¹⁰Department of Internal Medicine, University of Michigan; Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ¹¹Internal Medicine and Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Our work presented previously suggests recent GC use (up to 2 years prior…
Abstract Number: 2431 • ACR Convergence 2024
DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
doria Andrea¹, Ronald Van Vollenhoven², Eric Morand³, Catharina Lindholm⁴, Jonatan Hedberg⁴, Miina Waratani⁵ and Danuta Kielar⁶, ¹University of Padova, Padova, Italy, ²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁵Biopharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁶Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: 2023 EULAR recommendations for the management of SLE open up the option for early treatment initiation with biologics without the requirement to fail immunosuppressants/DMARDs…
Abstract Number: 1124 • ACR Convergence 2024
Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
Xiaodi Ruan¹, Michael Williams², Gul Karakoc¹, Elizabeth McNeer¹, Leena Choi¹, Jonathan D. Mosley¹, C. Michael Stein¹ and Vivian K. Kawai¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²VUMC, Nashville, TN
Background/Purpose: Glucocorticoids (GCs) are potent anti-inflammatory drugs that are commonly prescribed, particularly for rheumatic and immunologic conditions. Hyperglycemia is an important adverse effect and occurs…
Abstract Number: 1799 • ACR Convergence 2024
In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Jia Xin Chow¹, Rochelle Sherlock², Taylah Bennett², Eric Morand³ and Sarah Jones², ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Australia, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].